CAM
FATE icon

Cormorant Asset Management’s Fate Therapeutics FATE Stock Holding History

Cormorant Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,000
Closed -$824K – 110
2021
Q1 		$824K Hold
10,000
– – 0.02% 114
2020
Q4 		$909K Sell
10,000
-5,000
-33% -$310K 0.02% 100
2020
Q3 		$600K Sell
15,000
-35,000
-70% -$1.22M 0.02% 92
2020
Q2 		$1.72M Sell
50,000
-25,000
-33% -$745K 0.07% 79
2020
Q1 		$1.67M Buy
+75,000
New +$1.9M 0.08% 72

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cormorant Asset Management's FATE Position: Q2 2021 in Review

Cormorant Asset Management sold out of Fate Therapeutics (FATE) in Q2 2021, closing a stake of 10,000 shares — an estimated $824K sold.

Cormorant Asset Management first reported a position in FATE in Q1 2020 and held it in 5 quarters. The position peaked at $1.72M in Q2 2020. 272 funds tracked by Wall St. Rank hold FATE as of Q2 2021.

  • Cormorant Asset Management reported no remaining Fate Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 10,000 Fate Therapeutics shares in Q2 2021, an estimated $824K.
  • Cormorant Asset Management first reported a position in Fate Therapeutics in Q1 2020 and held it in 5 quarters.
  • Cormorant Asset Management's Fate Therapeutics position peaked at $1.72M in Q2 2020.
  • 272 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.